Page 296 - Drug Class Review
P. 296
Page 178 of 205
Drug Effectiveness Review Project
placebo NR 12.5% 8% 0% placebo 20% NR
tacrine NR 51% 30% 14% Yes, but significance not reported Post randomization exclusions: Yes (6) Overall loss to follow-up: 44% Loss to follow-up differential high: Yes tacrine 52% NR
ITT: Yes NR NR NR Poor
Final Report Update 1 Authors: Wong et al. Year: 1999 ADVERSE EVENTS: Overall adverse effects reported: Elevated ALT • Anorexia • Nausea/Vomiting • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
